

**Advancing Primary and Endocrinology Care in Chronic Kidney Disease and Heart Failure:  
Guideline-Based Strategies to Improve Cardiorenal Outcomes**

**TOOLKIT**

**Prevalence: The Why?**

| Resource                                                                                                                                                                                                                                     | Address                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes Obes Metab</i> . 2020;22:1607-1618. | <a href="https://pubmed.ncbi.nlm.nih.gov/32363737/">https://pubmed.ncbi.nlm.nih.gov/32363737/</a>                                    |
| CDC website. Chronic kidney disease in the United States, 3/31/2026.                                                                                                                                                                         | <a href="http://www.cdc.gov/kidney-disease/php/data-research/index.html">www.cdc.gov/kidney-disease/php/data-research/index.html</a> |
| Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. <i>J Am Soc Nephrol</i> . 2005;16:489-495.            | <a href="https://pubmed.ncbi.nlm.nih.gov/15590763/">https://pubmed.ncbi.nlm.nih.gov/15590763/</a>                                    |
| International Diabetes Federation. <i>IDF Diabetes Atlas</i> . 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.                                                                                                           | <a href="https://diabetesatlas.org/resources/previous-editions/">https://diabetesatlas.org/resources/previous-editions/</a>          |
| Jha V, Al-Ghamdi SMG, Li G, et al. Global economic burden associated with chronic kidney disease: A pragmatic review of medical costs for the inside CKD research programme. <i>Adv Ther</i> . 2023;40:4405-4420. y                          | <a href="https://pubmed.ncbi.nlm.nih.gov/37493856/">https://pubmed.ncbi.nlm.nih.gov/37493856/</a>                                    |
| Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. <i>Kidney Int Suppl</i> (2011). 2022;12:7-11.                                                                                                                            | <a href="https://pubmed.ncbi.nlm.nih.gov/35529086/">https://pubmed.ncbi.nlm.nih.gov/35529086/</a>                                    |
| Vanholder R, Annemans L, Bello AK, et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. <i>Clin Kidney J</i> . 2021;14:1719-1730.                                                                 | <a href="https://academic.oup.com/ckj/article/14/7/1719/6243030">https://academic.oup.com/ckj/article/14/7/1719/6243030</a>          |

**Pathophysiology, Screening, and Diagnosis of CKD and HF**

| Resource                                                                                                                                                                                                                                                                                             | Address                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Handelsman Y, Butler J, Bakris GL, et al. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <i>J Diabetes Complications</i> . 2023;37:108389.                                                                                              | <a href="https://pubmed.ncbi.nlm.nih.gov/36669322/">https://pubmed.ncbi.nlm.nih.gov/36669322/</a> |
| Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> . 2022;145:e876-e894. | <a href="https://pubmed.ncbi.nlm.nih.gov/35363500/">https://pubmed.ncbi.nlm.nih.gov/35363500/</a> |
| Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> . 2022;145:e895-e1032.                   | <a href="https://pubmed.ncbi.nlm.nih.gov/35363499/">https://pubmed.ncbi.nlm.nih.gov/35363499/</a> |
| Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. <i>Am J Kidney Dis</i> . 2014;63:713-735.                                                                                                             | <a href="https://pubmed.ncbi.nlm.nih.gov/24647050/">https://pubmed.ncbi.nlm.nih.gov/24647050/</a> |

| Resource                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Address                                                                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kaye J, Maggiore P. Medical Forum website. Cardio-metabolic renal syndrome and cardiovascular disease risk, 4/21/2025.                                                                                                                                                                                                                                                                                                                                                                             | <a href="https://mforum.com.au/cardio-metabolic-renal-syndrome-and-cardiovascular-disease-risk/">https://mforum.com.au/cardio-metabolic-renal-syndrome-and-cardiovascular-disease-risk/</a> |
| KDIGO CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int.</i> 2024;105(4 suppl):S117-S314.                                                                                                                                                                                                                                                                                                                          | <a href="https://pubmed.ncbi.nlm.nih.gov/38490803/">https://pubmed.ncbi.nlm.nih.gov/38490803/</a>                                                                                           |
| KDIGO Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int.</i> 2022;102(5 suppl):S1-S127.                                                                                                                                                                                                                                                                                                                                 | <a href="https://pubmed.ncbi.nlm.nih.gov/36272764/">https://pubmed.ncbi.nlm.nih.gov/36272764/</a>                                                                                           |
| Khan MS, Shahid I, Anker SD, et al. Albuminuria and heart failure: JACC state-of-the-art review. <i>J Am Coll Cardiol.</i> 2023;81:270-282.                                                                                                                                                                                                                                                                                                                                                        | <a href="https://pubmed.ncbi.nlm.nih.gov/36653095/">https://pubmed.ncbi.nlm.nih.gov/36653095/</a>                                                                                           |
| McCullough PA, Amin A, Pantalone KM, et al. Cardiorenal nexus: A review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. <i>J Am Heart Assoc.</i> 2022;11:e024139.                                                                                                                                                                                                                                                                               | <a href="https://pubmed.ncbi.nlm.nih.gov/35616212/">https://pubmed.ncbi.nlm.nih.gov/35616212/</a>                                                                                           |
| Morris AA, Khazanie P, Drazner MH, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Hypertension. Guidance for timely and appropriate referral of patients with advanced heart failure: A scientific statement from the American Heart Association. <i>Circulation.</i> 2021;144:e238-e250. | <a href="https://pubmed.ncbi.nlm.nih.gov/34503343/">https://pubmed.ncbi.nlm.nih.gov/34503343/</a>                                                                                           |
| Mukoyama M, Kuwabara T. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use? <i>Hypertens Res.</i> 2022;45:1072-1075.                                                                                                                                                                                                                                                                                                                                                  | <a href="https://pubmed.ncbi.nlm.nih.gov/35361929/">https://pubmed.ncbi.nlm.nih.gov/35361929/</a>                                                                                           |
| Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: An individual-participant data meta-analysis. <i>JAMA.</i> 2023;330:1266-1277.                                                                                                                                                                                                                                                                                            | <a href="https://pubmed.ncbi.nlm.nih.gov/37787795/">https://pubmed.ncbi.nlm.nih.gov/37787795/</a>                                                                                           |
| Zannad F and Rossignol P. Cardiorenal syndrome revisited. <i>Circulation.</i> 2018;138:929-944.                                                                                                                                                                                                                                                                                                                                                                                                    | <a href="https://pubmed.ncbi.nlm.nih.gov/30354446/">https://pubmed.ncbi.nlm.nih.gov/30354446/</a>                                                                                           |

#### Clinical Updates and Treatment Guidelines

| Resource                                                                                                                                                                                                                                                             | Address                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>Eur Heart J.</i> 2022;43:474-484. | <a href="https://pubmed.ncbi.nlm.nih.gov/35023547/">https://pubmed.ncbi.nlm.nih.gov/35023547/</a>                                                                                                                                                                                                                                                                                                                                               |
| Agarwal R, Green JB, Heerspink HJL, et al; CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. <i>N Engl J Med.</i> 2025;393:533-543.                                                                             | <a href="https://pubmed.ncbi.nlm.nih.gov/40470996/">https://pubmed.ncbi.nlm.nih.gov/40470996/</a>                                                                                                                                                                                                                                                                                                                                               |
| Agarwal R, et al. HiD 2021; Poster.                                                                                                                                                                                                                                  | <a href="https://images.search.yahoo.com/yhs/search?p=Heart+in+Diabetes%2C+2021%2C+agarwal%2C+FIDELIO+abstract&amp;fr=yhs-aol-aol_portal&amp;hspart=aol&amp;hsimp=yhs-aol_portal&amp;imgurl=https%3A%2F%2Fchronickidneydi">https://images.search.yahoo.com/yhs/search?p=Heart+in+Diabetes%2C+2021%2C+agarwal%2C+FIDELIO+abstract&amp;fr=yhs-aol-aol_portal&amp;hspart=aol&amp;hsimp=yhs-aol_portal&amp;imgurl=https%3A%2F%2Fchronickidneydi</a> |

| Resource                                                                                                                                                                                                                                                  | Address                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                           | sease.medicalaffairs.bayer.com%2Fsites%2Fg%2Ffiles%2Fvrxlpx56786%2Ffiles%2F2022-09%2F2021_HiD_Agarwal_CREDENCE_FIDELIO-DKD.png#id=3&iurl=https%3A%2F%2Fchronickidneydisease.medicalaffairs.bayer.com%2Fsites%2Fg%2Ffiles%2Fvrxlpx56786%2Ffiles%2F2022-09%2F2021_HiD_Agarwal_CREDENCE_FIDELIO-DKD.png&action=click                                                         |
| Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD study investigators. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. <i>Am J Nephrol</i> . 2019;50:333-344. | <a href="https://pubmed.ncbi.nlm.nih.gov/31655812/">https://pubmed.ncbi.nlm.nih.gov/31655812/</a>                                                                                                                                                                                                                                                                         |
| Bexagliflozin (Brenzavvy™) PI, 9/2023.                                                                                                                                                                                                                    | <a href="https://brenzavvydirect.com/wp-content/uploads/2024/10/Brenzavvy-Prescribing-Information-PI-001-09_FINAL.pdf">https://brenzavvydirect.com/wp-content/uploads/2024/10/Brenzavvy-Prescribing-Information-PI-001-09_FINAL.pdf</a>                                                                                                                                   |
| Blazek O and Bakris GL. The evolution of "pillars of therapy" to reduce heart failure risk and slow diabetic kidney disease progression. <i>Am Heart J Plus</i> . 2022;19:100187.                                                                         | <a href="https://pubmed.ncbi.nlm.nih.gov/38558865/">https://pubmed.ncbi.nlm.nih.gov/38558865/</a>                                                                                                                                                                                                                                                                         |
| Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. <i>N Engl J Med</i> . 2001;345:861-869.                                  | <a href="https://pubmed.ncbi.nlm.nih.gov/11565518/">https://pubmed.ncbi.nlm.nih.gov/11565518/</a>                                                                                                                                                                                                                                                                         |
| Canagliflozin (Invokana®) PI, 12/2024. Johnson & Johnson website.                                                                                                                                                                                         | <a href="http://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf">www.jnjlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf</a>                                                                                                                                                                |
| Dapagliflozin (Farxiga®) PI, 10/2024.                                                                                                                                                                                                                     | <a href="https://drd9vr9dh9yh09.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition_v.pdf">https://drd9vr9dh9yh09.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition_v.pdf</a> |
| Desai AS, Swedberg K, McMurray JJV, et al; CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>J Am Coll Cardiol</i> . 2007;50:1959-1966.                          | <a href="https://pubmed.ncbi.nlm.nih.gov/17996561/">https://pubmed.ncbi.nlm.nih.gov/17996561/</a>                                                                                                                                                                                                                                                                         |
| Empagliflozin (Jardiance®) prescribing information (PI), 1/26. Boehringer Ingelheim website.                                                                                                                                                              | <a href="https://content.boehringer-ingelheim.com/DAM/7d9c411c-ec33-4f82-886f-af1e011f35bb/jardiance-us-pi.pdf">https://content.boehringer-ingelheim.com/DAM/7d9c411c-ec33-4f82-886f-af1e011f35bb/jardiance-us-pi.pdf</a>                                                                                                                                                 |
| EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al; Empagliflozin in patients with chronic kidney disease. <i>N Engl J Med</i> . 2023;388:117-127.                                                                                | <a href="https://pubmed.ncbi.nlm.nih.gov/36331190/">https://pubmed.ncbi.nlm.nih.gov/36331190/</a>                                                                                                                                                                                                                                                                         |
| Ertugliflozin (Steglatro®) PI, 12/2024.                                                                                                                                                                                                                   | <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209803s008lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209803s008lbl.pdf</a> ¶                                                                                                                                                                                                   |
| Gerstein HC, Sattar N, Rosenstock J, et al; AMPLITUDE-O                                                                                                                                                                                                   | <a href="https://pubmed.ncbi.nlm.nih.gov/34215025/">https://pubmed.ncbi.nlm.nih.gov/34215025/</a>                                                                                                                                                                                                                                                                         |

| Resource                                                                                                                                                                                                                                                                                                           | Address                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. <i>N Engl J Med</i> . 2021;385:896-907.                                                                                                                                                                              |                                                                                                   |
| Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> . 2019;394:121-130.                                                                                     | <a href="https://pubmed.ncbi.nlm.nih.gov/31189511/">https://pubmed.ncbi.nlm.nih.gov/31189511/</a> |
| Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. <i>Lancet</i> . 2000;355:253-259. | <a href="https://pubmed.ncbi.nlm.nih.gov/10675071/">https://pubmed.ncbi.nlm.nih.gov/10675071/</a> |
| Heerspink HJL, Stefansson BV, Chertow GM, et al; DAPA-CKD Investigators. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrol Dial Transplant</i> . 2020;35:274-282.                                        | <a href="https://pubmed.ncbi.nlm.nih.gov/32030417/">https://pubmed.ncbi.nlm.nih.gov/32030417/</a> |
| Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i> . 2017;377:1228-1239.                                                                                                                               | <a href="https://pubmed.ncbi.nlm.nih.gov/28910237/">https://pubmed.ncbi.nlm.nih.gov/28910237/</a> |
| Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <i>N Engl J Med</i> . 2019;381:841-851.                                                                                                                        | <a href="https://pubmed.ncbi.nlm.nih.gov/31185157/">https://pubmed.ncbi.nlm.nih.gov/31185157/</a> |
| Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. <i>N Engl J Med</i> . 2001;345:851-860.                                                                          | <a href="https://pubmed.ncbi.nlm.nih.gov/11565517/">https://pubmed.ncbi.nlm.nih.gov/11565517/</a> |
| Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med</i> . 2016;375:311-322.                                                                                                          | <a href="https://pubmed.ncbi.nlm.nih.gov/27295427/">https://pubmed.ncbi.nlm.nih.gov/27295427/</a> |
| Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <i>N Engl J Med</i> . 2016;375:1834-1844.                                                                                                                                  | <a href="https://pubmed.ncbi.nlm.nih.gov/27633186/">https://pubmed.ncbi.nlm.nih.gov/27633186/</a> |
| McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med</i> . 2014;371:993-1004.                                                                                                                    | <a href="https://pubmed.ncbi.nlm.nih.gov/25176015/">https://pubmed.ncbi.nlm.nih.gov/25176015/</a> |
| Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. <i>N Engl J Med</i> . 2019;380:2295-2306.                                                                                                                                | <a href="https://pubmed.ncbi.nlm.nih.gov/30990260/">https://pubmed.ncbi.nlm.nih.gov/30990260/</a> |
| Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on                                                                                                                                                                                                        | <a href="https://pubmed.ncbi.nlm.nih.gov/38785209/">https://pubmed.ncbi.nlm.nih.gov/38785209/</a> |

| Resource                                                                                                                                                                                                                                                               | Address                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| chronic kidney disease in patients with type 2 diabetes. <i>N Engl J Med</i> . 2024;391:109-121.                                                                                                                                                                       |                                                                                                                                                                 |
| Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. <i>N Engl J Med</i> . 2015;373:2247-2257.                                                                                       | <a href="https://pubmed.ncbi.nlm.nih.gov/26630143/">https://pubmed.ncbi.nlm.nih.gov/26630143/</a>                                                               |
| Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med</i> . 1999;341:709-717.                                         | <a href="https://pubmed.ncbi.nlm.nih.gov/10471456/">https://pubmed.ncbi.nlm.nih.gov/10471456/</a>                                                               |
| Rentoukas EI, Lazaros GA, and Ziogiannis PN. Aldosterone in heart and kidney diseases. <i>Hellenic J Cardiol</i> . 2005;46:408-419.                                                                                                                                    | <a href="https://pubmed.ncbi.nlm.nih.gov/16422128/">https://pubmed.ncbi.nlm.nih.gov/16422128/</a>                                                               |
| Ruilope LM, Agarwal R, Anker SD, et al; FIGARO-DKD study investigators. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease Trial. <i>Am J Nephrol</i> . 2019;50:345-356.              | <a href="https://pubmed.ncbi.nlm.nih.gov/31665733/">https://pubmed.ncbi.nlm.nih.gov/31665733/</a>                                                               |
| Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes Endocrinol</i> . 2021;9:653-662. | <a href="https://pubmed.ncbi.nlm.nih.gov/34425083/">https://pubmed.ncbi.nlm.nih.gov/34425083/</a>                                                               |
| The SOLVD investigators; Yusuf S, Pitt B, Davis CE. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. <i>N Engl J Med</i> . 1991;325:293-302.                                                 | <a href="https://pubmed.ncbi.nlm.nih.gov/2057034/">https://pubmed.ncbi.nlm.nih.gov/2057034/</a>                                                                 |
| Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med</i> . 2019;381:1609-1620.                                                     | <a href="https://pubmed.ncbi.nlm.nih.gov/31475794/">https://pubmed.ncbi.nlm.nih.gov/31475794/</a>                                                               |
| Sotagliflozin (Inpefa®) PI, 1/2024. Lex Pharma website.                                                                                                                                                                                                                | <a href="http://www.lexpharma.com/inpefa-US-PI.pdf">www.lexpharma.com/inpefa-US-PI.pdf</a>                                                                      |
| Tuttle KR, Hauske SJ, Canziani ME, et al; ASi in CKD Group. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. <i>Lancet</i> . 2024;403:379-390.               | <a href="https://pubmed.ncbi.nlm.nih.gov/38109916/">https://pubmed.ncbi.nlm.nih.gov/38109916/</a>                                                               |
| Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrol Dial Transplant</i> . 2020;35:1700-1711.                                          | <a href="https://pubmed.ncbi.nlm.nih.gov/32862232/">https://pubmed.ncbi.nlm.nih.gov/32862232/</a>                                                               |
| Williams DL, et al. SGLT-2 inhibitors. The gift that keeps on giving. <i>Medicine Today</i> . 2023;24:63-67.                                                                                                                                                           | <a href="https://medicinetoday.com.au/system/files/pdf/MT2023-04-063-WILLIAMS.pdf">https://medicinetoday.com.au/system/files/pdf/MT2023-04-063-WILLIAMS.pdf</a> |
| Zannad F, McMurray JJV, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med</i> . 2011;364:11-21.                                                                                            | <a href="https://pubmed.ncbi.nlm.nih.gov/21073363/">https://pubmed.ncbi.nlm.nih.gov/21073363/</a>                                                               |

## Guideline Recommendations for HF and CKD Treatment

| Resource                                                                                                                                                                                                                                                                                                                  | Address                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Heidenreich PA, Bozkurt B, Aguilar D, et al; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> . 2022 May 3;145:e895-e1032. | <a href="https://pubmed.ncbi.nlm.nih.gov/35363499/">https://pubmed.ncbi.nlm.nih.gov/35363499/</a> |
| Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney Int</i> . 2022;102:S1-S127.                                                                                                                    | <a href="https://pubmed.ncbi.nlm.nih.gov/36272764/">https://pubmed.ncbi.nlm.nih.gov/36272764/</a> |
| Neuen BL, Tuttle KR, and Vaduganathan M. Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease. <i>Circulation</i> . 2024;149:1238-1240.                                                                                                             | <a href="https://pubmed.ncbi.nlm.nih.gov/38620082/">https://pubmed.ncbi.nlm.nih.gov/38620082/</a> |

| Resource                                                                                                                                                                                    | Address                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Rangaswami J, Tuttle KR, and Vaduganathan M. Cardio-renal-metabolic care models: Toward achieving effective interdisciplinary care. <i>Circ Cardiovasc Qual Outcomes</i> . 2020;13:e007264. | <a href="https://pubmed.ncbi.nlm.nih.gov/33176463/">https://pubmed.ncbi.nlm.nih.gov/33176463/</a> |

All URLs accessed May 14, 2026.